According to the company, the one-year Target Validation Funding Award will support pathway validation experiments to show the efficacy of novel biased ligands to the delta-opioid receptor in treating Parkinson’s disease.
Based on scientific evidence, Trevena suggests that its proprietary biased ligands avoid the on-target mediated convulsions found with traditional delta-opioid agonists, offering the possibility of a new approach to treat Parkinson’s disease symptoms.
Trevena Chief Scientific Officer Michael Lark said the foundation has established itself in the field of Parkinson’s disease treatments.
"We are thrilled to become part of that scientific community and to apply our novel scientific approach to address the burden of this disease for patients and their families," Lark added.